Jesús de la Fuente

Jesús de la Fuente

Auto-generated profile, based on publicly available information

Jesús de la Fuente

Tecnun School of Engineering, University of Navarra Department of Biomedical Engineering and Science 20018 San Sebastian

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2025 in Nature Machine Intelligence
Verified
Journal Article
Open access
PDF file
JFJesus de la Fuente
Jesus de la Fuente
GSGuillermo Serrano
Guillermo Serrano
UVUxía Veleiro
Uxía Veleiro
MCMikel Casals
Mikel Casals
LÁLaura Vera Álvarez
Laura Vera Álvarez
MHMikel Hernaez
Mikel Hernaez
Drug–target interaction (DTI) prediction is a challenging albeit essential task in drug repurposing. Learning on graph models has drawn special attention as they can substantially reduce drug repurposing costs and time commitment. However, many current approaches require high-demand additional information besides DTIs that complicates their evaluation process and usability. Additionally, structural differences in the learning architecture of current models hinder their fair benchmarking. In this work, we first perform an in-depth evaluation of current DTI datasets and prediction models through a robust benchmarking process and show that DTI methods based on transductive models lack generalization and lead to inflated performance when traditionally evaluated, making them unsuitable for drug repurposing. We then propose a biologically driven strategy for negative-edge subsampling and uncovered previously unknown interactions via in vitro validation, missed by traditional subsampling. Finally, we provide a toolbox from all generated resources, crucial for fair benchmarking and robust model design.

13 February 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
CBCharles Blatti
Charles Blatti
JFJesús de la Fuente
Jesús de la Fuente
HGHuanyao Gao
Huanyao Gao
IMIrene Marín-Goñi
Irene Marín-Goñi
ZCZikun Chen
Zikun Chen
MHMikel Hernaez
Mikel Hernaez
Survival rates of patients with metastatic castration-resistant prostate cancer (mCRPC) are low due to lack of response or acquired resistance to available therapies, such as abiraterone (Abi). A better understanding of the underlying molecular mechanisms is needed to identify effective targets to overcome resistance. Given the complexity of the transcriptional dynamics in cells, differential gene expression analysis of bulk transcriptomics data cannot provide sufficient detailed insights into resistance mechanisms. Incorporating network structures could overcome this limitation to provide a global and functional perspective of Abi resistance in mCRPC. Here, we developed TraRe, a computational method using sparse Bayesian models to examine phenotypically driven transcriptional mechanistic differences at three distinct levels: transcriptional networks, specific regulons, and individual transcription factors (TF). TraRe was applied to transcriptomic data from 46 patients with mCRPC with Abi-response clinical data and uncovered abrogated immune response transcriptional modules that showed strong differential regulation in Abi-responsive compared with Abi-resistant patients. These modules were replicated in an independent mCRPC study. Furthermore, key rewiring predictions and their associated TFs were experimentally validated in two prostate cancer cell lines with different Abi-resistance features. Among them, ELK3, MXD1, and MYB played a differential role in cell survival in Abi-sensitive and Abi-resistant cells. Moreover, ELK3 regulated cell migration capacity, which could have a direct impact on mCRPC. Collectively, these findings shed light on the underlying transcriptional mechanisms driving Abi response, demonstrating that TraRe is a promising tool for generating novel hypotheses based on identified transcriptional network disruptions. Significance: The computational method TraRe built on Bayesian machine learning models for investigating transcriptional network structures shows that disruption of ELK3, MXD1, and MYB signaling cascades impacts abiraterone resistance in prostate cancer.

22 December 2023 in Acta Ophthalmologica
Verified
Journal Article
Open access
JFJesus de la Fuente
Jesus de la Fuente
SLSara Llorente-González
Sara Llorente-González
PFPatricia Fernandez-Robredo
Patricia Fernandez-Robredo
MHMaría Hernandez
María Hernandez
AGAlfredo Garcia-Layana
Alfredo Garcia-Layana
SGSpanish AMD group
Spanish AMD group
Purpose: To assess the suitability of machine learning (ML) techniques in predicting the development of fibrosis and atrophy in patients with neovascular age‐related macular degeneration (nAMD), receiving anti‐VEGF treatment over a 36‐month period.Methods: An extensive analysis was conducted on the use of ML to predict fibrosis and atrophy development on nAMD patients at 36 months from start of anti‐VEGF treatment, using only data from the first 12 months. We use data collected according to real‐world practice, which includes clinical and genetic factors.Results: The ML analysis consistently identified ETDRS as a relevant factor for predicting the development of atrophy and fibrosis, confirming previous statistical analyses. Also, it was shown that genetic variables did not demonstrate statistical relevance in the prediction. Despite the complexity of predicting macular degeneration, our model was able to obtain a balance accuracy of 63% and an AUC of 0.72 when predicting the development of atrophy or fibrosis at 36 months.Conclusion: This study demonstrates the potential of ML techniques in predicting the development of fibrosis and atrophy in nAMD patients receiving long‐term anti‐VEGF treatment. The findings highlight the importance of clinical factors, particularly ETDRS (early treatment diabetic retinopathy study) visual acuity test, in predicting these outcomes. The lessons learned from this research can guide future ML‐based prediction tasks in the field of ophthalmology and contribute to the design of data collection processes.

27 August 2025 in Nucleic Acids Research
Verified
Journal Article
Open access
JFJesús de la Fuente
Jesús de la Fuente
NLNaroa Legarra-Marcos
Naroa Legarra-Marcos
ADAintzane Diaz-Mazkiaran
Aintzane Diaz-Mazkiaran
GSGuillermo Serrano
Guillermo Serrano
IMIrene Marín-Goñi
Irene Marín-Goñi
MHMikel Hernaez
Mikel Hernaez
Deconvolution models are a powerful tool for extracting cell-type-specific information from bulk gene expression profiles. Current methods leverage advanced machine learning models and high-resolution sequencing, like single-cell RNA-sequencing, showing promising results across diverse tissues and conditions. However, they still present important limitations: First, many depend on selecting a robust reference, which can strongly affect the deconvolution. Second, pseudobulk data used for training and real bulk RNA-seq samples often exhibit strong distribution shifts, which are currently unaccounted for. Finally, most deconvolution approaches behave as black boxes, which can compromise the reliability of the results. Here, we present Sweetwater, an adaptive and interpretable autoencoder that efficiently deconvolves bulk samples leveraging multiple classes of reference data. Moreover, we propose an improved way of generating training data from a mixture of FACS-sorted FASTQ files, reducing platform-specific biases and outperforming current single-cell-based references. Furthermore, we introduce a gold standard dataset to facilitate fair and accurate evaluation of deconvolution approaches. Finally, we demonstrate that Sweetwater adapts effectively to deconvolved samples during training, uncovering biologically meaningful patterns and enhancing result’s reliability. Sweetwater is available at https://doi.org/10.6084/m9.figshare.29609180, and we anticipate it will expedite the accurate examination of high-throughput clinical data across diverse applications.

24 November 2025
Verified
Other
Open access
CBCharles Blatti
Charles Blatti
JFJesús de la Fuente
Jesús de la Fuente
HGHuanyao Gao
Huanyao Gao
IMIrene Marín-Goñi
Irene Marín-Goñi
ZCZikun Chen
Zikun Chen
MHMikel Hernaez
Mikel Hernaez
Excel file with regulon edges and ChIP-seq enrichment scores for TraRe, GRNboost2 and ARACNE-AP

14 April 2023
Verified
Other
Open access
CBCharles Blatti
Charles Blatti
JFJesús de la Fuente
Jesús de la Fuente
HGHuanyao Gao
Huanyao Gao
IMIrene Marín-Goñi
Irene Marín-Goñi
ZCZikun Chen
Zikun Chen
MHMikel Hernaez
Mikel Hernaez
Supplementary Notes (S1-S5)Supplementary Tables (S1 - S5; S10 - S11)Supplementary Figures (S1 - S12)